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Abstract Sustained exposure of neuroblastoma x glioma hybrid, NG108-15, ceils transfected toexpress the human fl2-adrenoceptor (clone fiN22) 
to isoprenaline or iloprost (an agonist at the endogenously expressed IP prostanoid receptor) resulted in a substantial nd selective down-regulation 
of the ct subunit of the G-protein Gs. Treatment of these cells with the irreversible fl-adrenoceptor antagonist bromoacetyl a prenolol menthane 
diminished both the potency and the maximal ability of isoprenaline but not of iloprost o cause G~ct down-regulation. These results demonstrate 
that the extent of agonist-mediated Gsct down-regulation is dependent upon the availability of receptor to agonist. 
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1. Introduction 
Agonist-mediated selective down-regulation of the G-pro- 
tein(s) activated upon receptor occupancy has become a well 
established phenomenon [1]. However, despite this, in many 
systems little or no detectable regulation is observed. For exam- 
ple, in neuroblastomax glioma hybrid, NGI08-15, cells ag- 
onists at each of the endogenously expressed IP prostanoid, 
adenosine A2 and secretin receptors cause stimulation of ade- 
nylyl cyclase but only those at the IP prostanoid receptor cause 
down-regulation of G~ct [2,3]. This effect is not mimicked by 
analogues of cAMP [3] and we have hypothesised that G-pro- 
tein down-regulation may reflect the levels of expression of the 
individual receptors [4]. As there are technical limitations in the 
ability to accurately quantitate ach of these receptors we have 
transfected NG108-15 cells to express the human fl2-adreno- 
ceptor [5,6] and in the present s udy regulate agonist access to 
the receptor population by pretreatment of the cells with vary- 
ing concentrations of an irreversible fl-adrenoceptor antagonist 
to determine directly the importance of receptor levels in the 
observation of agonist-mediated down-regulation of Gs~. 
2. Materials and methods 
2.1. Materials 
All materials for tissue culture were from Gibco/BRL. [3H]Dihydro- 
alprenolol (56 Ci/mmol) was from Amersham International. Bro- 
moacetyl alprenolol menthane (BAAM) was from RBI (Natick, MA, 
USA). All other chemicals were from Sigma or BDH and were of the 
highest purity available. 
2.2. Generation of clone fiN22 
Has previously been described in detail [5-6]. A cDNA encoding the 
human fl2-adrenoceptor was ligated downstream of the fl-actin pro- 
moter of plasmid pJM16 [7] which harbours a copy of the neomycin 
resistance gene. 10/tg of this purified DNA was stably transfected into 
NG 108-15 ceils using Lipofectin reagent (Gibco/BRL) according to the 
manufacturers instructions. Clone fiN22 was one of those selected and 
expanded [5-6]. 
2.3. Cell growth 
Clone fiN22 cells were grown in tissue culture as previously described 
[5,6] in the presence of geneticin sulphate (800/lg/ml). Prior to conflu- 
ency they were either split 1:10 into fresh tissue culture flasks or 
harvested. Membrane fractions were prepared from cell pastes which 
had been stored at -80°C following harvest essentially as in [8]. Frozen 
cell pellets were suspended in 5 ml 10 mM Tris-HCl, 0.1 mM EDTA, 
pH 7.5 (buffer A) and rupture of the cells achieved with 25 strokes of 
a hand-held teflon on glass homogenizer. The resulting homogenate 
was centrifuged at 500 x g for 10 min in a Beckman L5-50B centrifuge 
with a Ti 50 rotor to remove unbroken cells and nuclei. The supernatant 
fraction from this treatment was then centrifuged at 48,000 x g for 10 
min and the pellet from this treatment washed and resuspended in 10 
ml buffer A. Following a second centrifugation at 48,000 x g for 10 min 
the membrane pellet was resuspended in buffer A to a final protein 
concentration between 1-3 mg/ml and stored at -80°C until required. 
2.4. Treatment of cells 
Cells of clone fiN22 were treated in culture with either iloprost (up 
to 10/~M) (Schering Health Care, Burgess Hill, Sussex, UK) or with 
isoprenaline (up to 10/IM) (Sigma) including vehicle ither without or 
following pretreatment of the cells with BAAM (up to 10/.tM) for 4 h. 
Preliminary studies indicated that the vehicles and BAAM alone had 
no effect on levels of G,ct over the time course of the treatments (data 
not shown). 
2.5. Production of antisera nd immunoblotting 
Antiserum CS was produced by a New Zealand White rabbit follow- 
ing immunization with a glutaraldehyde conjugate of keyhole limpet 
haemocyanin (Calbiochem) and a synthetic peptide, RMHLRQYELL, 
which corresponds to the C-terminal decapeptide ofall forms of the ct 
subunit of G,. The specificity of this antiserum for G~ct has previously 
been demonstrated [9]. Immunoblotting with this antiserum was per- 
formed as previously described [10]. Molecular mass determinations 
were based on pre-stained molecular-mass markers (Bethesda Research 
Laboratories). SDS-polyacrylamide g l electrophoresis (SDS-PAGE) 
(10% (w/v) acrylamide) was carried out overnight at 60 V. 
*Corresponding author. Fax: (44) (41) 330 4620. 
Abbreviations." BAAM, bromoacetyl alprenolol menthane; DHA, dihy- 
droalprenolol. 
2.6. Quantitation of immunoblots 
Following SDS-PAGE, proteins were transferred to nitrocellulose 
(Schleicher and Schuell) and blocked for 2 h in 5% gelatin in phosphate- 
buffered saline, pH 7.5 (PBS). Primary antisera were added in 1% 
gelatin in PBS containing 0.2% Nonidet P40 (NP 40) and incubated for 
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at least 2 h. The primary antiserum wasthen removed and the blot 
washed extensively with PBS containing 0.2% NP40. Secondary antise- 
rum (donkey anti-rabbit IgG coupled to horseradish peroxidase (Scot- 
tish Antibody Production Unit, Wishaw, Scotland) was added (1:200 
dilution in 1% gelatin in PBS containing 0.2% NP 40) and incubated 
with the nitrocellulose for 2 h. The antiserum was then removed and 
following extensive washing of the blot with PBS containing 0.2% NP40 
and finally with PBS alone, the blot was developed using o-dianisidine 
hydrochloride (Sigma) as the substrate for horseradish peroxidase as 
previously described [10]. The developed immunoblots were scanned 
with a Biorad model GS-670 Imaging densitometer. Background was 
subtracted by scanning of equivalent sized areas of nitrocellulose which 
did not contain immunoreactive protein. 
2. 7. Binding experiments with [3 H]dihydroalprenolol 
Were routinely performed with 2.0 nM [3H]dihydroalprenolol 
([3H]DHA) at 30°C for 30 min in 20 mM Tris-HC1 (pH 7.5), 50 mM 
sucrose, 20 mM MgC12 (buffer B) in the absence and presence of10/aM 
propranolol to define maximal and non-specific binding respectively. 
Specific binding, defined as above, represented greater than 90% of the 
total binding of [3H]DHA. All binding experiments were terminated by 
rapid filtration through Whatman GF/C fdters followed by three 
washes (5 ml) with ice-cold buffer B. 
2.8. Adenylyl cyclase assays 
These were performed as described by Milligan et al. [11]. Each assay 
contained 100 mM Tris-HC1, pH 7.5, 20 mM creatine phosphate, 50 
mM NaCI, 5 mM MgCI2, 1 mM cAMP, 1/aM GTP, 10 units creatine 
phosphokinase and 0.2 mM ATP containing 1/aCi [ct-32p]ATP. Separa- 
tion of radiolabelled cyclic AMP and ATP was achieved using the 
double column method described by Johnson and Salomon [12]. 
2.9. Data analysis 
All data were analysed using the Kaleidograph (Version 2.1) curve 
fitting programme driven by an Apple Mclntosh computer. 
3. Results 
Membranes derived from cells of clone fiN22, which was 
generated following transfection of neuroblastoma x glioma 
hybrid, NG108-15, cells with a plasmid containing a eDNA 
encoding the human fl2-adrenoceptor [5,6], were examined for 
expression of this receptor by measuring the specific binding of 
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Fig. 1. Treatment of clone fiN22 cells with BAAM prevents subsequent 
binding of [3H]DHA. Clone fiN22 ceils in tissue culture were untreated 
or treated with varying concentrations of BAAM for 4 h. Cells were 
subsequently harvested and membranes prepared. The specific binding 
of [3H]DHA (2 nM) to these membranes was ubsequently assessed as
described in section 2. 
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Fig. 2. Treatment ofclone fiN22 cells with BAAM restricts fl2-adreno- 
ceptor but not IP prostanoid receptor agonist-mediated down-regula- 
tion of G,~. fiN22 cells were untreated (control) or treated with BAAM 
(10 pM) for 4 h, washed extensively and then either left in he absence 
of ligand (CON) or challenged with iloprost (10 pM) (ILO) or isopre- 
naline (10/aM) (ISO) for 8 h. The cells were harvested, membranes 
generated and immunoblotted for the presence of G,~t.Data are pre- 
sented as means + S.D. from 3 separate experiments. 
the fl-adrenoceptor antagonist [3H]DHA (2 nM). Exposure of 
clone fiN22 cells to varying concentrations of the irreversible 
fl-adrenoceptor antagonist BAAM for 4 h prior to cell harvest 
and membrane preparation resulted in a decrease in the number 
of detectable specific binding sites for [3H]DHA (Fig. 1). In the 
absence of BAAM some 3000 fmol/mg membrane protein of 
fl2-adrenoceptor binding sites were available in the passages of 
the cells used to specifically bind [3H]DHA and this was re- 
duced by approximately 90% by treatment with l0/2M BAAM. 
Half-maximal reduction in specific [3H]DHA binding was ob- 
tained by treatment with some 30 nM BAAM. 
Sustained (8 h) exposure of clone fiN22 cells to maximally 
effective concentrations of either the IP prostanoid receptor 
agonist, iloprost (10/2M) or the fl-adrenoceptor agonist isopre- 
naline (10 pM) resulted in some 50% down-regulation f cellu- 
lar levels of the ~ subunit of the stimulatory G-protein of the 
adenylyl cyclase cascade, Gs (Fig. 2). Such treatments did not 
alter cellular levels of other G-proteins expressed by these cells 
(data not shown but see [5]). Following pretreatment of he cells 
with BAAM (10/aM, 4 h) no alteration in the ability of this 
concentration f iloprost o down-regulate G,ct was noted. By 
contrast, a substantial reduction in the effect of 10 gM isopre- 
naline was observed (Fig. 2). This pattern of reduced effective- 
ness of isoprenaline to cause down-regulation f G,0t was ob- 
served over a range of isoprenaline concentrations (Fig. 3a,b) 
following treatment with 10 pM BAAM. At all concentrations 
of isoprenaline t sted the degree of down-regulation f G,0t was 
reduced and there was a substantial shift (some 50-fold) to 
higher concentrations in the requirement for isoprenaline to 
cause half-maximal reduction in Gs0t levels (Fig. 3b). By con- 
trast, no significant alteration in the dose-effect curve for 
iloprost-mediated Gs~ down-regulation was observed following 
such treatment with BAAM (data not shown). 
Preincubation f cells of clone fiN22 with varying concentra- 
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tions of BAAM (1 nM-10/aM) followed by subsequent expo- 
sure to a maximally effective dose of isoprenaline (10/aM) 
demonstrated that the ability of the agonist o cause G,ct down- 
regulation was compromised as increasing numbers of the fl2- 
adrenoceptor were eliminated (Fig. 4). Half-maximal reduction 
in the ability of 10/aM isoprenaline to cause limination of G,ct 
was obtained following treatment with 100 nM BAAM (Fig. 4). 
Even following treatment with 10/aM BAAM the maximal 
ability of isoprenaline to stimulate adenylyl cyclase activity in 
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Fig. 4. The effect of BAAM on isoprenaline-induced down-regulation 
of G,~t; dose-effect analysis. Cells of clone fiN22 were untreated or 
treated for 4 h with varying concentrations ofBAAM and subsequently 
with isoprenaline (10 pM, 8 h). Relative levels of G,~ in membranes 
from these cells were then assessed immunologically. Data is presented 
as the % of the membrane Gsct which was downregulated by isoprenal- 
ine at each concentration f BAAM. 
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membranes of fiN22 cells was only slightly lower than in mem- 
branes of untreated cells although the dose-effect curve for 
isoprenaline was shifted to significantly higher concentrations 
(Fig. 5). Overall, these results demonstrate hat the degree of 
agonist-mediated down-regulation of Gs~ reflects the number 
of receptors available to agonist. 
4. Discussion 
Although agonist-induced down-regulation f receptors has 
been studied for many years and is appreciated to provide a 
means to regulate cellular sensitivity to agonist ligands [13] the 
concept hat agonist reatment can also regulate the cellular 
content of G-proteins has taken longer to be accepted and has 
been more recalcitrant toanalysis. In a variety of circumstances 
sustained exposure of a cell to an agonist ligand does result in 
a substantial reduction in cellular levels of the G-protein(s) 
which is activated by the receptor (see [1] for review). However, 
such effects are not observed for all systems and for all agonists. 
For example, in the neuroblastoma x glioma hybrid cell line, 
NG 108-15, treatment with agonists at the IP prostanoid recep- 
tor but not with agonists ateither the adenosine A2 or secretin 
4-- 
Fig. 3. BAAM treatment of clone fiN22 cells reduces the potency of 
isoprenaline-mediated G~ down-regulation. Cells of clone fiN22 were 
untreated or treated with BAAM (10 pM, 4 h) and subsequently chal- 
lenged with varying concentrations of isoprenaline for 8 h. Membranes 
were prepared and the relative levels of G,ct determined immunologi- 
cally. (a) Immunoblots. (A) Treated with BAAM, (B) not treated with 
BAAM. Subsequent treatment with isoprenaline: 1,control; 2, 100 pM; 
3, 1 nM; 4, 10 nM; 5, 100 nM; 6, 1/JM; 7, 10 pM. (b) Quantitative 
analysis. The data of Fig. 3a was analysed and is displayed as the % 
of maximal effect of isoprenaline (produced by 10/JM) on membrane 
levels of G,ct. In the example displayed the estimated ECs0 for isoprenal- 
ine-induced down-regulation of G,~ was 1.3 nM in the cells which ad 
not been exposed to BAAM (filled symbols) and 78 nM in the cells 
which had been pretreated with BAAM (open symbols). Similar results 
were obtained in two other independent experiments. 
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Fig. 5. The effect of BAAM on isoprenaline stimulation of adenylyl 
cyclase activity. Membranes were prepared from control (open sym- 
bols) and BAAM (10/~M, 4 h)-treated (filled symbols)fiN22 cells and 
the ability of varying concentrations f i oprenaline to stimulate ade- 
nylyl cyclase activity measured. Results are presented as % of the 
maximal effect of isoprenaline in membranes of untreated cells. 
receptors results in a substantial down-regulation f G,~ even 
though all of these receptors couple to Gs~ and thus cause 
activation of adenylyl cyclase [2,3]. As addition of analogues of 
cAMP or agents able to elevate intracellular cAMP in a non- 
receptor-dependent fashion is unable to mimic the effect of 
prostanoid agonists [3] we have argued that the differences 
between the receptor ligands is unlikely to represent the ability 
of each receptor to activate adenylyl c clase and may reflect he 
levels of cellular expression of each receptor [4]. This, however, 
has been difficult to establish clearly in these cells as only 
agonist 3H-ligands are available for use in binding studies for 
the IP prostanoid and secretin receptors and there have been 
concerns as to whether ligands for the adenosine A2 receptor 
may label other sites [14] such as the adenosine transporter. 
We have recently established clonal cell lines following trans- 
fection of NG108-15 cells with a cDNA encoding the human 
fl2-adrenoceptor [5,6] and indeed a clone expressing high levels 
of the receptor (some 4,000 fmol/mg membrane protein) re- 
sponded to challenge with isoprenaline bydown-regulating lev- 
els of G,~ whereas little effect was observed in a lcone express- 
ing much lower levels (300 fmol/mg membrane protein) of the 
receptor [5]. While such results provide strong supportive vi- 
dence for the concept hat agonist-mediated G-protein down- 
regulation is likely to reflect levels of expression of a receptor 
they suffer from the fact that they had to be performed on 
different individual clonal isolates. To counteract this concern 
in the present study we have used a single clone (fiN22) which 
expresses relatively high levels of the fl2-adrenoceptor and then 
limited access of isoprenaline to the receptor by pretreating the 
cells with varying concentrations of the irreversible fl-adreno- 
ceptor antagonist BAAM. We make a number of key observa- 
tions. (i) BAAM (10 aM, 4 h) treatment of clone fiN22 cells 
results in a substantial reduction in the maximal down-regula- 
tion of G,~ which can be achieved by isoprenaline without 
altering the amount of down-regulation of G,ct produced by 
occupancy of the IP prostanoid receptor by iloprost (Fig. 2). 
(ii) Half-maximal down-regulation of G,~ which can be pro- 
duced by isoprenaline required substantially higher levels of the 
agonist following treatment with BAAM (10/tM) compared to 
the control cells (Fig. 3). (iii) Dose--effect urves for iloprost- 
mediated own-regulation f G,~t were unaffected by treatment 
with BAAM. (iv) Treatment of clone fiN22 cells with a concen- 
tration of BAAM sufficient o reduce the amount of [3H]DHA 
to some 300 fmol/mg membrane protein substantially reduced, 
but did not eliminate ntirely, isoprenaline-induced down-regu- 
lation of G~. Such treatment, however, resulted in only a small 
reduction in the maximal ability of isoprenaline to stimulate 
adenylyl cyclase activity. (v) A 50% reduction in the maximal 
ability of isoprenaline to regulate G~t levels was produced by 
treatment of the cells with 100 nM BAAM, a concentration able 
to block agonist access to some 70% of the receptor population. 
These data demonstrate directly that the degree of G-protein 
down-regulation bserved is related to the number of receptors 
available for the agonist ligand to occupy and not to the ability 
of this receptor occupancy to result in the activation of adenylyl 
cyclase. This should be anticipated as previous studies have 
shown that such effects are restricted to the G-protein activated 
by the receptor [1,3,15], that the effect is a reflection of en- 
hanced egradation of the G-protein without significant tran- 
scriptional of translational control [1,16], that it is not mim- 
icked by treatment with analogues of cAMP [3] and because 
mutationally activated G-protein ~ subunits are known to have 
reduced half-lives compared with the wild type proteins [1,17]. 
Thus, if greater levels of available receptors are able to activate 
more copies of the G-protein then greater down-regulation f
this polypeptide should be anticipated. However, the observa- 
tions that reduction of fl2-adrenoceptor availability levels in 
clone fiN22 cells to some 300 fmol/mg membrane protein still 
resulted in a detectable down-regulation of Gs~t whereas this 
was not observed in clone flNl7 which expresses this level of 
receptor endogenously [5] clearly demonstrates that it is unwise 
to extrapolate results from data obtained in different clonal 
isolates. 
Gs~ is expressed at some 1.25 x i0  6 copies per cell and the 
IP prostanoid receptor at some 105 copies per cell in NG108-15 
cells and in the transfected clonal cell lines derived from it [18]. 
In clone fiN22 the fl2-adrenoceptor is expressed at some 3-4- 
fold higher levels than the IP prostanoid receptor [5,6]. We have 
previously calculated that the IP prostanoid receptor can acti- 
vate some 65% of the cellular G,0t in NG108-15 cells [19] and 
therefore if the fl2-adrenoceptor is able to activate the G-pro- 
tein with similar stoichiometry then less than maximal occu- 
pancy of this receptor would be expected to result in maximal 
down-regulation f G~t as indeed we observe herein. 
It should be noted that in this system each 10% down-regula- 
tion represents a loss of some 105 copies per cell of G,~t. The 
inability to observe detectable G-protein down-regulation i  a 
range of systems may thus be a reflection of a combination of 
the levels of receptor expression and that of the G-protein. 
Clearly in cells which express high levels of a G-protein, agonist 
may be able to cause down-regulation f only a small fraction 
of the polypeptide and this would be virtually undetectable 
when measured immunologically. Equally it is unlikely to be 
observed with agonists at receptors which are expressed at only 
low levels. This may then provide the explanation for the inabil- 
ity of either secretin or an A2 adenosine receptor agonist o 
alter Gs~ levels detectably in NGI08-15 cells [2,20]. The use of 
irreversible antagonists at a range of receptor systems will allow 
assessment ofwhether the conclusions reached in this study are 
widely applicable. 
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